Melanie Drolet, Ph.D.

2005 Universite Laval (Canada) 
Public Health, Industrial Psychology
"Melanie Drolet"
Cross-listing: Neurotree


Sign in to add mentor
Elizabeth Maunsell grad student 2005 Universite Laval (Canada)
 (Experience au travail apres un cancer du sein.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Humphries B, Lauzier S, Drolet M, et al. (2019) Wage losses among spouses of women with nonmetastatic breast cancer. Cancer
Mesher D, Soldan K, Lehtinen M, et al. (2016) Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases. 22: 1732-1740
Brisson M, Laprise JF, Chesson HW, et al. (2016) Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Journal of the National Cancer Institute. 108
Drolet M, Bénard É, Boily MC, et al. (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. The Lancet. Infectious Diseases. 15: 565-80
Malagón T, Drolet M, Boily MC, et al. (2015) Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 276-85
Laprise JF, Drolet M, Boily MC, et al. (2014) Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 32: 5845-53
Jit M, Choi YH, Laprise JF, et al. (2014) Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine. 32: 3237-42
Drolet M, Laprise JF, Boily MC, et al. (2014) Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. International Journal of Cancer. Journal International Du Cancer. 134: 2264-8
Drolet M, Boily MC, Van de Velde N, et al. (2013) Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? Plos One. 8: e67072
Brisson M, Laprise JF, Drolet M, et al. (2013) Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 31: 3863-71
See more...